Literature DB >> 25424911

Rapid proliferation of activated lymph node CD4(+) T cells is achieved by greatly curtailing the duration of gap phases in cell cycle progression.

Takuya Mishima1, Shoko Toda, Yoshiaki Ando, Tsukasa Matsunaga, Manabu Inobe.   

Abstract

Peripheral T cells are in G0 phase and do not proliferate. When they encounter an antigen, they enter the cell cycle and proliferate in order to initiate an active immune response. Here, we have determined the first two cell cycle times of a leading population of CD4(+) T cells stimulated by PMA plus ionomycin in vitro. The first cell cycle began around 10 h after stimulation and took approximately 16 h. Surprisingly, the second cell cycle was extremely rapid and required only 6 h. T cells might have a unique regulatory mechanism to compensate for the shortage of the gap phases in cell cycle progression. This unique feature might be a basis for a quick immune response against pathogens, as it maximizes the rate of proliferation.

Entities:  

Mesh:

Year:  2014        PMID: 25424911      PMCID: PMC6275717          DOI: 10.2478/s11658-014-0219-z

Source DB:  PubMed          Journal:  Cell Mol Biol Lett        ISSN: 1425-8153            Impact factor:   5.787


  17 in total

1.  IL-2 secretion by CD4+ T cells in vivo is rapid, transient, and influenced by TCR-specific competition.

Authors:  Dorothy K Sojka; Denis Bruniquel; Ronald H Schwartz; Nevil J Singh
Journal:  J Immunol       Date:  2004-05-15       Impact factor: 5.422

2.  Proliferating CD4+ T cells undergo immediate growth arrest upon cessation of TCR signaling in vivo.

Authors:  Cory A Yarke; Stacy L Dalheimer; Na Zhang; Drew M Catron; Marc K Jenkins; Daniel L Mueller
Journal:  J Immunol       Date:  2008-01-01       Impact factor: 5.422

3.  Correlated measurements of DNA, RNA, and protein in individual cells by flow cytometry.

Authors:  H A Crissman; Z Darzynkiewicz; R A Tobey; J A Steinkamp
Journal:  Science       Date:  1985-06-14       Impact factor: 47.728

4.  Distinct signal transduction in mouse CD4+ and CD8+ splenic T cells after CD28 receptor ligation.

Authors:  R Abe; P Vandenberghe; N Craighead; D S Smoot; K P Lee; C H June
Journal:  J Immunol       Date:  1995-02-01       Impact factor: 5.422

5.  p27Kip1 regulates T cell proliferation.

Authors:  S Mohapatra; D Agrawal; W J Pledger
Journal:  J Biol Chem       Date:  2001-04-10       Impact factor: 5.157

6.  Characterization of a monoclonal antibody, HTA28, recognizing a histone H3 phosphorylation site as a useful marker of M-phase cells.

Authors:  Akihiro Hirata; Ken-Ichi Inada; Tetsuya Tsukamoto; Hiroki Sakai; Tsutomu Mizoshita; Tokuma Yanai; Toshiaki Masegi; Hidemasa Goto; Masaki Inagaki; Masae Tatematsu
Journal:  J Histochem Cytochem       Date:  2004-11       Impact factor: 2.479

Review 7.  The role of naive T cell precursor frequency and recruitment in dictating immune response magnitude.

Authors:  Marc K Jenkins; James J Moon
Journal:  J Immunol       Date:  2012-05-01       Impact factor: 5.422

8.  Commitment point during G0-->G1 that controls entry into the cell cycle.

Authors:  Nicholas C Lea; Stephen J Orr; Kai Stoeber; Gareth H Williams; Eric W-F Lam; Mohammad A A Ibrahim; Ghulam J Mufti; N Shaun B Thomas
Journal:  Mol Cell Biol       Date:  2003-04       Impact factor: 4.272

9.  Concanavalin A-mediated T cell proliferation is regulated by herpes virus entry mediator costimulatory molecule.

Authors:  Yoshiaki Ando; Chika Yasuoka; Takuya Mishima; Takuya Ikematsu; Toshimitsu Uede; Tsukasa Matsunaga; Manabu Inobe
Journal:  In Vitro Cell Dev Biol Anim       Date:  2013-10-26       Impact factor: 2.416

10.  Identification of multiple cell cycle regulatory functions of p57Kip2 in human T lymphocytes.

Authors:  Guiming Li; Joanne Domenico; Joseph J Lucas; Erwin W Gelfand
Journal:  J Immunol       Date:  2004-08-15       Impact factor: 5.422

View more
  1 in total

Review 1.  Memory CD4+ T Cells in Immunity and Autoimmune Diseases.

Authors:  Itay Raphael; Rachel R Joern; Thomas G Forsthuber
Journal:  Cells       Date:  2020-02-25       Impact factor: 6.600

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.